News

Filter

Current filters:

Immunology

1 to 9 of 10 results

Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products

Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products

02-09-2014

Allergopharma, a division of Germany’s Merck KGaA, and Austrian allergy biotechnology company S-TARget…

AllergopharmaAustriaBiotechnologyGermanyImmunologyInflammatory diseasesMerck KGaAResearch

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11-08-2014

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Roche’s…

Anti-Arthritics/RheumaticsImmunologyImmunosuppressantsNHSPharmaceuticalRegulationRoActemraRocheTocilizumabUK

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

30-07-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a clinical study collaboration…

AstraZenecaBriggs MorrisonImmunologyJapanKyowa Hakko KirinOncologyPharmaceuticalResearchUK

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

23-07-2014

Shares of US biotech firm Biogen Idec jumped 7.35% to $326 in pre-market trading today, as the company…

AlprolixBiogen IdecBiotechnologyElocateFinancialImmunologyPharmacologyTecfideraUSA

Stallergenes expands in Latin American with acquisition of Alergo Pharma

Stallergenes expands in Latin American with acquisition of Alergo Pharma

22-07-2014

French allergen specialist Stallergenes said this morning that it has acquired full ownership of Alergo…

Alergo PharmaAllergologyArgentinaImmunologyMedicineMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryStallergenes

Immunocore and Eli Lilly sign $25 million collaboration

Immunocore and Eli Lilly sign $25 million collaboration

16-07-2014

UK-based biotech firm Immunocore and US drug major Eli Lilly today announced they have entered into a…

BiotechnologyEli LillyImmunocoreImmunologyLicensingLillyOncologyUKUSA

Executive Q&A: Paul Higham, CEO of immatics

Executive Q&A: Paul Higham, CEO of immatics

27-05-2014

In an interview with The Pharma Letter, immatics chief executive Paul Higham discusses the company's…

BiotechnologyCancerGermanyHealth Medical Pharmaimmatics biotechnologiesImmunologyInterviewsMedicineOncologyVaccination

New psoriasis therapies go head-to-head with existing drugs

06-05-2014

Three promising new drug classes are heating up the market for moderate-to-severe plaque psoriasis therapeutics,…

AlphaCytokinesDermatologicalsGlobalImmunologyMarkets & MarketingModerate-to-severe plaque psoriasisPharmaceuticalPharmacology

1 to 9 of 10 results

Back to top